Published in Proc Natl Acad Sci U S A on October 15, 1992
The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J (1997) 6.36
PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell (2011) 4.00
Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci U S A (1996) 3.24
A Mef2 gene that generates a muscle-specific isoform via alternative mRNA splicing. Mol Cell Biol (1994) 2.30
Myogenin and MEF2 function synergistically to activate the MRF4 promoter during myogenesis. Mol Cell Biol (1995) 1.39
Transient expression of a winged-helix protein, MNF-beta, during myogenesis. Mol Cell Biol (1997) 1.36
Synergistic interactions between heterologous upstream activation elements and specific TATA sequences in a muscle-specific promoter. Mol Cell Biol (1995) 1.32
An E box in the desmin promoter cooperates with the E box and MEF-2 sites of a distal enhancer to direct muscle-specific transcription. EMBO J (1994) 1.25
Differences between MyoD DNA binding and activation site requirements revealed by functional random sequence selection. Mol Cell Biol (1996) 1.09
A combination of MEF3 and NFI proteins activates transcription in a subset of fast-twitch muscles. Mol Cell Biol (1997) 1.07
MyoD and myogenin act on the chicken myosin light-chain 1 gene as distinct transcriptional factors. Mol Cell Biol (1993) 0.96
HEN1 encodes a 20-kilodalton phosphoprotein that binds an extended E-box motif as a homodimer. Mol Cell Biol (1994) 0.95
DNA binding and transcriptional activation by the Ski oncoprotein mediated by interaction with NFI. Nucleic Acids Res (1997) 0.94
A muscle-specific enhancer within intron 1 of the human dystrophin gene is functionally dependent on single MEF-1/E box and MEF-2/AT-rich sequence motifs. Nucleic Acids Res (1997) 0.88
Nfix Regulates Temporal Progression of Muscle Regeneration through Modulation of Myostatin Expression. Cell Rep (2016) 0.85
Lineage-based primary muscle fiber type diversification independent of MEF2 and NFAT in chick embryos. J Muscle Res Cell Motil (2011) 0.83
Differential expression of the myocyte enhancer factor 2 family of transcription factors in development: the cardiac factor BBF-1 is an early marker for cardiogenesis. Mol Cell Biol (1994) 0.83
TREMOR--a tool for retrieving transcriptional modules by incorporating motif covariance. Nucleic Acids Res (2007) 0.82
Novel muscle-specific enhancer sequences upstream of the cardiac actin gene. Mol Cell Biol (1994) 0.82
Basic helix-loop-helix factors recruit nuclear factor I to enhance expression of the NaV 1.4 Na+ channel gene. Biochim Biophys Acta (2007) 0.82
Multiplex selection technique (MuST): an approach to clone transcription factor binding sites. Proc Natl Acad Sci U S A (1996) 0.80
Extracellular deposition of matrilin-2 controls the timing of the myogenic program during muscle regeneration. J Cell Sci (2014) 0.79
Genetic variation in the porcine myogenin gene locus. Mamm Genome (1997) 0.75
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol (1987) 26.70
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell (1989) 21.54
Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell (1989) 14.24
Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. Science (1990) 9.54
Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell (1989) 8.42
MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell (1989) 6.94
Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell (1991) 6.48
A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. EMBO J (1989) 6.37
The interplay of DNA-binding proteins on the promoter of the mouse albumin gene. Cell (1987) 6.14
A gene with homology to the myc similarity region of MyoD1 is expressed during myogenesis and is sufficient to activate the muscle differentiation program. Genes Dev (1989) 5.91
A sensitive method for the determination of protein-DNA binding specificities. Nucleic Acids Res (1990) 5.42
A new myocyte-specific enhancer-binding factor that recognizes a conserved element associated with multiple muscle-specific genes. Mol Cell Biol (1989) 4.72
Upstream regions of the human cardiac actin gene that modulate its transcription in muscle cells: presence of an evolutionarily conserved repeated motif. Mol Cell Biol (1986) 4.59
Identification of MRF4: a new member of the muscle regulatory factor gene family. Genes Dev (1989) 4.50
Whole genome PCR: application to the identification of sequences bound by gene regulatory proteins. Nucleic Acids Res (1989) 4.07
Cyclic amplification and selection of targets (CASTing) for the myogenin consensus binding site. Mol Cell Biol (1991) 3.54
Herculin, a fourth member of the MyoD family of myogenic regulatory genes. Proc Natl Acad Sci U S A (1990) 3.30
Myogenin resides in the nucleus and acquires high affinity for a conserved enhancer element on heterodimerization. Genes Dev (1990) 3.18
Myf-6, a new member of the human gene family of myogenic determination factors: evidence for a gene cluster on chromosome 12. EMBO J (1990) 3.16
MyoD binds cooperatively to two sites in a target enhancer sequence: occupancy of two sites is required for activation. Proc Natl Acad Sci U S A (1990) 3.14
The TGGCA protein binds to the MMTV-LTR, the adenovirus origin of replication, and the BK virus enhancer. Nucleic Acids Res (1985) 2.93
HEB, a helix-loop-helix protein related to E2A and ITF2 that can modulate the DNA-binding ability of myogenic regulatory factors. Mol Cell Biol (1992) 2.72
Purification of a NF1-like DNA-binding protein from rat liver and cloning of the corresponding cDNA. EMBO J (1988) 2.60
Differential trans activation associated with the muscle regulatory factors MyoD1, myogenin, and MRF4. Mol Cell Biol (1990) 1.95
Transcriptional activation domain of the muscle-specific gene-regulatory protein myf5. Nature (1990) 1.94
Analysis of nuclear factor I binding to DNA using degenerate oligonucleotides. Nucleic Acids Res (1986) 1.71
HTF4: a new human helix-loop-helix protein. Nucleic Acids Res (1991) 1.43
Transformation-defective v-ski induces MyoD and myogenin expression but not myotube formation. Mol Cell Biol (1991) 1.11
The four human muscle regulatory helix-loop-helix proteins Myf3-Myf6 exhibit similar hetero-dimerization and DNA binding properties. Nucleic Acids Res (1991) 1.09
Alternative multimeric structures affect myogenin DNA binding activity. J Biol Chem (1992) 0.94
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 20.48
Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet (1997) 6.69
A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol (1992) 6.56
Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell (1991) 6.48
Positive autoregulation of the myogenic determination gene MyoD1. Cell (1989) 4.28
Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet (1999) 4.22
A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res (1991) 4.07
Defining the molecular mechanisms of human cell immortalization. Biochim Biophys Acta (1991) 3.73
Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis. Nature (1989) 3.73
Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev (1999) 3.19
Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev (2001) 3.16
Telomere position effect in human cells. Science (2001) 2.61
Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci U S A (1999) 2.36
Telomerase and cancer. Hum Mol Genet (2001) 2.28
E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene (1993) 2.25
Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol (2000) 2.15
Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J Biol Chem (2000) 2.14
Telomerase activity in human cancer. Curr Opin Oncol (1996) 2.13
Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins. Mol Cell Biol (1994) 2.00
Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp Cell Res (1989) 1.96
Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro. Mol Cell Biol (1999) 1.96
The establishment of telomerase-immortalized cell lines representing human chromosome instability syndromes. Hum Mol Genet (2000) 1.93
Regulation of telomerase activity in immortal cell lines. Mol Cell Biol (1996) 1.82
Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res (2001) 1.73
Telomere shortening is proportional to the size of the G-rich telomeric 3'-overhang. J Biol Chem (2000) 1.73
Identification of skeletal muscle precursor cells in vivo by use of MyoD1 and myogenin probes. Cell Tissue Res (1992) 1.67
Biliary excretion of cephalosporins in rats: influence of molecular weight. Antimicrob Agents Chemother (1980) 1.63
Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene (1993) 1.59
Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol Cell Biol (1999) 1.55
Transient expression of human telomerase extends the life span of normal human fibroblasts. Biochem Biophys Res Commun (2000) 1.54
Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc Natl Acad Sci U S A (1985) 1.54
Formation of anucleate and multinucleate cells in normal and SV 40 transformed WI-38 by cytochalasin B. Exp Cell Res (1972) 1.50
An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia (2001) 1.48
Telomerase immortalization of human myometrial cells. Biol Reprod (2002) 1.48
Increasing trends in the use of breast-conserving surgery in California. Am J Public Health (2000) 1.44
Leukaemia in workers exposed to electrical and magnetic fields. Lancet (1982) 1.43
Telomeres and telomerase: a simple picture becomes complex. Cell (1996) 1.41
Pulmonary effects of exposures in silicon carbide manufacturing. Br J Ind Med (1984) 1.39
Multiple myeloma in cosmetologists. Am J Ind Med (1982) 1.38
Induction of muscle genes in neural cells. J Cell Biol (1984) 1.36
Telomeres and telomerase: implications for cancer and aging. Radiat Res (2001) 1.34
Cephaloglycin and its biologically active metabolite desacetylcephaloglycin. Appl Microbiol (1971) 1.34
Malignant mesothelioma: incidence, asbestos exposure, and reclassification of histopathology. Br J Ind Med (1984) 1.34
Hallmarks of telomeres in ageing research. J Pathol (2007) 1.33
A conserved motif N-terminal to the DNA-binding domains of myogenic bHLH transcription factors mediates cooperative DNA binding with pbx-Meis1/Prep1. Nucleic Acids Res (1999) 1.32
The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res (1993) 1.32
Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol (1996) 1.30
Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci U S A (1997) 1.30
Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells. J Biol Chem (2001) 1.28
Recent trends in mesothelioma incidence in the United States. Am J Ind Med (1986) 1.28
Telomerase activity concentrates in the mitotically active segments of human hair follicles. J Invest Dermatol (1997) 1.25
Telomerase activity does not always imply telomere maintenance. Biochem Biophys Res Commun (1999) 1.25
The isolation of heterokaryons and hybrids by a selective system using irreversible biochemical inhibitors. Exp Cell Res (1978) 1.25
Expression of differentiated functions in heterokaryons between skeletal myocytes, adrenal cells, fibroblasts and glial cells. Exp Cell Res (1984) 1.24
Breast cancer stage at diagnosis in relation to duration of medicaid enrollment. Med Care (2001) 1.23
Is telomerase a viable target in cancer? Mutat Res (2011) 1.23
Heterogeneous nuclear ribonucleoproteins C1 and C2 associate with the RNA component of human telomerase. Mol Cell Biol (2000) 1.22
Characterization of ataxia telangiectasia fibroblasts with extended life-span through telomerase expression. Oncogene (2001) 1.18
Telomerase inhibitors. Trends Biotechnol (2001) 1.18
Use of reiterative selection for defining protein-nucleic acid interactions. Curr Opin Biotechnol (1995) 1.17
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res (1996) 1.17
Organic chemicals and malignant melanoma. Am J Ind Med (1983) 1.17
Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation. J Biol Chem (1997) 1.16
Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene (1993) 1.16
Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol (1996) 1.14
Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol (1997) 1.13
The suppression of myogenic functions in heterokaryons formed by fusing chick myocytes to diploid rat fibroblasts. Cell Differ (1983) 1.13
The reactivation of telomerase activity in cancer progression. Trends Genet (1996) 1.13
Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. Exp Gerontol (1996) 1.09
MyoD, myogenin independent differentiation of primordial myoblasts in mouse somites. J Cell Biol (1992) 1.06
Pancreas cancer is unrelated to the workplace in Los Angeles. Am J Ind Med (1985) 1.05
Respiratory disease in Utah coal miners. Am Rev Respir Dis (1981) 1.05
Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny. Oncogene (1996) 1.04
The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone (1988) 1.02
The orientation of rhodopsin and other pigments in dry films. J Gen Physiol (1972) 1.02
Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control (1999) 1.01
Synthesis of rat myosin light chains in heterokaryons formed between undifferentiated rat myoblasts and chick skeletal myocytes. J Cell Biol (1981) 1.00
Multiple pathways for the regulation of telomerase activity. Eur J Cancer (1997) 0.98
Complexes containing the retinoblastoma gene product recognize different DNA motifs related to the E2F binding site. Oncogene (1992) 0.97
Respiratory effects of borax dust. Br J Ind Med (1985) 0.97
Expression of the RNA component of telomerase during human development and differentiation. Cell Growth Differ (1998) 0.96
Characterisation of telomerase immortalised normal human oesophageal squamous cells. Gut (2003) 0.96
Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res (1997) 0.96
Noise trauma in the aetiology of acoustic neuromas in men in Los Angeles County, 1978-1985. Br J Cancer (1989) 0.95
Molecular biology of myogenic regulatory factors. Mol Biol Med (1991) 0.95
Alveolar bone necrosis and tooth loss. a rare complication associated with herpes zoster infection of the fifth cranial nerve. Oral Surg Oral Med Oral Pathol (1983) 0.94
Cancer among Hispanic children in California, 1988-1994: comparison with non-Hispanic white children. Cancer (1999) 0.94
Alternative multimeric structures affect myogenin DNA binding activity. J Biol Chem (1992) 0.94
Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry (1997) 0.94
Aging. When do telomeres matter? Science (2001) 0.94
The La antigen associates with the human telomerase ribonucleoprotein and influences telomere length in vivo. RNA (2001) 0.94
Ageing and cancer: the telomere and telomerase connection. Novartis Found Symp (2001) 0.94
Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J Natl Cancer Inst (2001) 0.93
Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control (2001) 0.93
Re-expression of senescent markers in deinduced reversibly immortalized cells. Exp Gerontol (1992) 0.93
Control of differentiation in heterokaryons and hybrids involving differentiation-defective myoblast variants. J Cell Biol (1984) 0.93
Myoblast senescence in muscular dystrophy. Exp Cell Res (1985) 0.92
Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene (2007) 0.92